Dongye Li
Overview
Explore the profile of Dongye Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
1248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu R, Ni J, Ren J, Li D, Xu J, Yu X, et al.
Front Oncol
. 2024 Nov;
14:1464125.
PMID: 39605897
In the era of transcriptomics, the role of epigenetics in the study of cancers in females has gained increasing recognition. This article explores the impact of epigenetic modifications, such as...
2.
Liu J, Ning Z, Du C, Chen S, Wang T, Cao J, et al.
J Cardiovasc Magn Reson
. 2024 Oct;
26(2):101112.
PMID: 39442673
Background: Accurate assessment of the vulnerability of carotid atherosclerotic plaques is crucial for stroke prevention. The three-dimensional (3D) magnetic resonance (MR) vessel wall imaging (VWI) has been increasingly employed to...
3.
Yang X, Zhang Q, Li D, Hu L, Wang Y, Yan X, et al.
Adv Healthc Mater
. 2024 Oct;
13(29):e2401398.
PMID: 39359011
Drug resistance resulting from diverse mechanisms including the presence of cancer stem cells (CSCs) is the main obstacle for improving therapeutic efficacy of lenvatinib in hepatocellular carcinoma (HCC). Herein, a...
4.
Cao M, Li Y, Tang Y, Chen M, Mao J, Yang X, et al.
Acad Radiol
. 2024 Jul;
32(1):334-346.
PMID: 39054246
Rationale And Objectives: The tumor-tropic properties of mesenchymal stem cells (MSCs) enable them to serve as appealing cellular vehicles for delivering therapeutic agents to treat malignant glioma. However, the exact...
5.
Li D, Chen J, Lu Y, Yan X, Yang X, Zhang F, et al.
Small
. 2024 Jun;
20(40):e2402673.
PMID: 38844996
Atherosclerosis (AS) is a common cause of coronary heart disease and stroke. The delivery of exogenous HS and in situ production of O within atherosclerotic plaques can help suppress inflammatory...
6.
Zhai Y, Chen J, Kan R, Xuan H, Wang C, Li D, et al.
Int Heart J
. 2024 Mar;
65(2):292-299.
PMID: 38556337
B-type natriuretic peptide (BNP) possesses protective cardiovascular properties; however, there has not been sufficient serious consideration of the side effects of BNP. As for sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a),...
7.
Yu Y, Li D, Lu Y, Mi J
PLoS One
. 2023 Dec;
18(12):e0295960.
PMID: 38100499
This study aimed to: (i) analyze the load characteristics of 4 weeks cross-country skiing altitude training; (ii) analyze the relationships between methods of monitoring training load and physiological indicators changes...
8.
Dai F, Xu X, Zhou C, Li C, Tian Z, Wang Z, et al.
Front Cardiovasc Med
. 2023 Dec;
10:1275710.
PMID: 38094123
Background: Acute ST-segment elevation myocardial infarction (STEMI) patients after primary PCI were readmitted for revascularization due to non-culprit lesion (NCL) progression. Objective: To develop and validate a nomogram that can...
9.
Luteolin Pretreatment Ameliorates Myocardial Ischemia/Reperfusion Injury by lncRNA-JPX/miR-146b Axis
Xu T, Zhang Y, Liao G, Xuan H, Yin J, Bao J, et al.
Anal Cell Pathol (Amst)
. 2023 Dec;
2023:4500810.
PMID: 38077523
Background: In the present study, we aimed to find out whether luteolin (Lut) pretreatment could ameliorate myocardial ischemia/reperfusion (I/R) injury by regulating the lncRNA just proximal to XIST (JPX)/microRNA-146b (miR-146b)...
10.
Liao G, Liu W, Dai Y, Shi X, Liu Y, Li D, et al.
iScience
. 2023 Nov;
26(11):108337.
PMID: 38026172
Atherosclerosis is the main cause of cardiovascular diseases that seriously endanger human health. The existing treatment drugs are effective, but they have some side effects. Accumulating evidence suggests that flavonoids...